$2.220
-0.087 (-3.90%)收盤時
MGNX 獲利能力與利潤率
Evaluating the bottom line, MacroGenics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -42.19%, while the net margin is -212.12%. These profitability ratios, combined with a Return on Equity (ROE) of -225.85%, provide a clear picture of how effectively MGNX converts its operational activities into shareholder value.
MGNX 同業比較
In the context of the broader market, MGNX competes directly with industry leaders such as PDSB and STRO. With a market capitalization of $141.41M, it holds a significant position in the sector. When comparing efficiency, MGNX's gross margin of 100.00% stands against PDSB's N/A and STRO's 100.00%. Such benchmarking helps identify whether MacroGenics Inc is trading at a premium or discount relative to its financial performance.
MacroGenics Inc 財務表現
The company has shown volatility in revenue, with a significant drop in Q2 2025 revenue to $6.87 million, but it rebounded to $32.83 million in Q2 2026. The gross margin has fluctuated, peaking at 100% in Q2 2025 and Q2 2026, but the overall financial performance remains inconsistent with recent net income swings from losses to profits.
Financials
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。